RxDoctor Payments Data

Elizabeth Eddy-Bertrand, MD

Family Medicine · Northridge, CANPI 1669573218

Payments from drug & device makers

$13,803in general payments, 2019–2025

Across 650 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$879
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$13,789100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,803 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$117,671
Medicare patients
241
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$145,807
JanuviaSitagliptin Phosphate71$97,772
FarxigaDapagliflozin Propanediol68$75,908
OzempicSemaglutide58$68,568
TrulicityDulaglutide38$50,951
EliquisApixaban29$33,373
XareltoRivaroxaban20$25,660
ProliaDenosumab15$25,261
MounjaroTirzepatide14$20,458
MyrbetriqMirabegron17$17,394
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,704
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,878
Atorvastatin Calcium813$7,876
EntrestoSacubitril/Valsartan12$7,645
PremarinEstrogens, Conjugated16$7,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$1,172$153,685101 claims
MerckJanuvia$437$97,77271 claims
AstraZenecaFarxiga$1,243$75,90868 claims
Lilly USA, LLCTrulicity, Mounjaro$879$71,40952 claims
Novo NordiskOzempic$675$68,56858 claims
PfizerEliquis, Premarin$705$40,46645 claims
Johnson & JohnsonXarelto$1,132$25,66020 claims
AmgenProlia$1,261$25,26115 claims
Astellas Pharma US IncMyrbetriq$393$17,39417 claims
GSKTrelegy Ellipta$449$10,70411 claims
NovartisEntresto$652$7,64512 claims
AbbVieSynthroid$1,888$2,54041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Northridge

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →